Suphamai Bunnapradist, MD
Enriched profileProfessor of Medicine, David Geffen School of Medicine at UCLA · University of California, Los Angeles
Suphamai Bunnapradist is Professor of Medicine, David Geffen School of Medicine at UCLA at University of California, Los Angeles. OpenAlex indexes 291 publications with 10,574 citations (h-index 61); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Suphamai Bunnapradist, M.D., is Professor of Medicine, David Geffen School of Medicine at UCLA at University of California, Los Angeles (David Geffen School of Medicine). The public record shows 291 publications with 10,574 citations (h-index 61), centered on Renal Transplantation Outcomes and Treatments, Organ Transplantation Techniques and Outcomes, Organ Donation and Transplantation. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 11 companies, 3 NIH-funded awards (2004–2021).
- Most recent indexed publication: 2026 · Journal of the American Society of Nephrology
- Top research focus: Renal Transplantation Outcomes and Treatments
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 11 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 151.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients
Sponsor: University of California, Los Angeles
- Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)
Sponsor: University of California, Los Angeles
Industry payments
Updated 27 Aug 2026
11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SANOFI-AVENTIS U.S. LLCProgram year202528 payments$40,746openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year202532 payments$37,270openpaymentsdata.cms.gov ↗
- Apellis Pharmaceuticals, Inc.Program year20255 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
36.3%Calcium channel blocker10.9%Amlodipine Besylate57%Nifedipine Er43%Part D<11 patientsBeta blocker10.2%Carvedilol100%Part D≥13 patientsMetabolism & gastrointestinal
30.9%Proton pump inhibitor17.6%Pantoprazole Sodium100%Part D≥19 patientsCorticosteroid13.3%Prednisone100%Part D≥24 patientsAnti-infectives
18.8%Short-acting sulfonamides9.4%Sulfamethoxazole-Trimethoprim100%Part D≥13 patientsCytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor4.7%Valganciclovir Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2004–2021 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Elevations in Donor-Derived Cell-Free DNA and Allograft Outcomes in Kidney Transplantation.
Journal of the American Society of Nephrology
Article2026 - Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians.
Annals of transplantation
Article2024 - Early cytomegalovirus DNAemia and antiviral dose adjustment in high vs intermediate risk kidney transplant recipients.
Transplant infectious disease
Article2021 - Time to second kidney transplantation in young adults after failed pediatric kidney transplant.
Pediatric transplantation
Article2020 - Screening Coccidioides serology in kidney transplant recipients: A 10-year cross-sectional analysis.
Transplant infectious disease
Article2018
Most-cited works
by citation count (OpenAlex)- 01Cell-Free DNA and Active Rejection in Kidney AllograftsArticle578 citations2017
- 02
- 03
- 04Posttransplant Malignancies in Solid Organ Adult RecipientsArticle211 citations2012
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/suphamai-bunnapradist-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Google Scholar
scholar.google.com/citations
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholar.google.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Suphamai-Bunnapradist-38965030
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
atc.digitellinc.com/b/sp/suphamai-bunnapradist-390
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →atc.digitellinc.com ↗ - Other
match.ucsf.edu/content/suphamai-bunnapradist-md-ms
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →match.ucsf.edu ↗ - Other
profiles.ucla.edu/suphamai.bunnapradist
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucla.edu ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Editorial & leadership roles
journal and society appointments- Associate Editor
Nephrology section, Frontiers in Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →frontiersin.org ↗ - Director of Research
Kidney Transplant Program, Ronald Reagan UCLA Medical Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →uclahealth.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uclahealth.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregg Fonarow, MD
University of California, Los Angeles
Dennis Slamon, MD
University of California, Los Angeles
Tomas Ganz, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles